You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

21 Results
Drug
Other Name(s): Alkeran®
Jun 2019
Drug
Other Name(s): Purinethol®
Jun 2019
Drug
Other Name(s): Lysodren®
Jun 2019
Drug
Other Name(s): Rydapt®
Jun 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    melphalan - oral tablets
ODB - General Benefit
    prednisone
Jun 2019
Regimen
Cancer Type:
Sarcoma, 
Desmoid Tumour
Intent: Curative
Jun 2019
Regimen
Cancer Type:
Sarcoma, 
Desmoid Tumour
Intent: Curative
Aug 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
  • melphalan - oral tablets
ODB - General Benefit
  • prednisone
Exceptional Access Program
  • thalidomide - Multiple myeloma in patients ≥65 years of age in combination with melphalan and prednisone, with specific criteria
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
ODB - General Benefit
  • methotrexate - oral tablets
May 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    melphalan - oral tablets
ODB - General Benefit
    dexamethasone
Sep 2019
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Palliative
Funding:
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - First-Line Treatment for Left-Sided Metastatic Colorectal Cancer
Jan 2025
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Intent: Curative
Funding:
ODB - General Benefit
    mercaptopurine
ODB - General Benefit
    prednisone
May 2019

Pages